Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases

被引:2
|
作者
Akiyama, Shintaro [1 ,3 ]
Fukuda, Soma [1 ]
Steinberg, Joshua M. [2 ]
Suzuki, Hideo [1 ]
Tsuchiya, Kiichiro [1 ]
机构
[1] Univ Tsukuba, Dept Gastroenterol, Tsukuba, Ibaraki 3058575, Japan
[2] Gastroenterol Rockies, Inflammatory Bowel Dis, Denver, CO 80218 USA
[3] Univ Tsukuba, Dept Gastroenterol, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
关键词
Inflammatory bowel disease; Phenotypes; Outcomes; Concurrent immune-mediated inflammatory diseases; PRIMARY SCLEROSING CHOLANGITIS; INNATE LYMPHOID-CELLS; ULCERATIVE-COLITIS; CELIAC-DISEASE; TAKAYASU ARTERITIS; CROHNS-DISEASE; SIGNALING PATHWAY; RISK LOCI; METAANALYSIS; AUTOIMMUNE;
D O I
10.3748/wjg.v28.i25.2843
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Patients with inflammatory bowel disease (IBD) are more likely to have concurrent immune-mediated inflammatory diseases (IMIDs) than those without IBD. IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies. Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes, and are considered to be at increased risk of requiring biologics and IBD-related surgeries, suggesting that having multiple IMIDs is a poor prognostic factor for IBD. Furthermore, IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes, suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions. In this review, we discuss the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concomitant IMIDs.
引用
收藏
页码:2843 / 2853
页数:11
相关论文
共 50 条
  • [1] Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases
    Shintaro Akiyama
    Soma Fukuda
    Joshua M Steinberg
    Hideo Suzuki
    Kiichiro Tsuchiya
    [J]. World Journal of Gastroenterology, 2022, 28 (25) : 2843 - 2853
  • [2] Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark
    Burisch, Johan
    Jess, Tine
    Egeberg, Alexander
    [J]. CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2019, 17 (13) : 2704 - +
  • [3] Vaccinations in patients with immune-mediated inflammatory diseases
    Rahier, Jean-Francois
    Moutschen, Michel
    Van Gompel, Alfons
    Van Ranst, Marc
    Louis, Edouard
    Segaert, Siegfried
    Masson, Pierre
    De Keyser, Filip
    [J]. RHEUMATOLOGY, 2010, 49 (10) : 1815 - 1827
  • [4] Genetics of immune-mediated inflammatory diseases
    David, T.
    Ling, S. F.
    Barton, A.
    [J]. CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 193 (01): : 3 - 12
  • [5] Reframing Immune-Mediated Inflammatory Diseases
    Boutrid, Nada
    Rahmoune, Hakim
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (21):
  • [6] Immune-mediated inflammatory diseases and psoriasis
    Delaporte, E.
    [J]. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2008, 135 : S269 - S274
  • [7] Inflammatory and Immune-Mediated Cutaneous Diseases
    Quaresma, Juarez A. S.
    Sotto, Mirian N.
    Balato, Anna
    [J]. MEDIATORS OF INFLAMMATION, 2017, 2017
  • [8] Adiponectin in inflammatory and immune-mediated diseases
    Fantuzzi, Giamila
    [J]. CYTOKINE, 2013, 64 (01) : 1 - 10
  • [9] Quality of Life in Patients with Immune-Mediated Inflammatory Diseases
    Russell, Anthony S.
    Gulliver, Wayne P.
    Irvine, E. Jan
    Albani, Salvatore
    Dutz, Jan P.
    [J]. JOURNAL OF RHEUMATOLOGY, 2011, 38 : 7 - 19
  • [10] Treatment Strategies for Patients With Immune-Mediated Inflammatory Diseases
    Curtis, Jeffrey R.
    Ogdie, Alexis
    George, Michael D.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (17): : 1726 - 1728